Jazz Pharmaceuticals Completes Acquisition of Chimerix
I'm PortAI, I can summarize articles.
Jazz Pharmaceuticals has acquired Chimerix, integrating it into its corporate strategy. The acquisition includes the Phase 3 ACTION trial, with Modeyso approval ahead of schedule. Expected revenue for 2025 is nearly $50 million, with further data anticipated by late 2026 or early 2027. The deal may reduce future cash taxes by about $200 million and includes a sale of a Priority Review Voucher for $200 million. The new asset has a peak sales potential exceeding $500 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments